AI assistant
Biocon Ltd. — Capital/Financing Update 2024
Jan 10, 2024
61176_rns_2024-01-10_55c0570a-75a4-4502-b350-e31951cb7581.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [132 x 52] intentionally omitted <==
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T: 91 80 2808 2808 F: 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com
BIO/SECL/EA/2023-24/144
January 10, 2024
| To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street,Mumbai – 400 001 |
To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 |
|---|---|
| Scrip Code – 532523 | Scrip Symbol - Biocon |
Subject: Intimation for the Board Meeting and Conference Call for Analysts and Investors
Dear Sir/Madam,
Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, February 08, 2024, inter alia, to approve and take on record the un-audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2023, amongst other routine matters.
The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading (‘the Code’) of the Company, has been closed from Monday, January 01, 2024 to Saturday, February 10, 2024 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations, 2015. Accordingly, the trading window will be opened from Sunday, February 11, 2024.
The Company will organize an Earnings Conference Call for analysts/investors on Friday, February 09, 2024. The details of the same is enclosed herewith.
The above-mentioned information will also be available on website of the Company at www.biocon.com.
Request you to take the above intimation on record.
Thanking You,
For Biocon Limited
Digitally signed MAYANK by MAYANK VERMA VERMA Date: 2024.01.10 16:52:56 +05'30'
Mayank Verma Company Secretary and Compliance Officer Membership No.: ACS 18776
Encl. as above.
==> picture [132 x 51] intentionally omitted <==
20th K.M. Hosur Road, Electronics City, Bangalore 560 100
Bangalore, 10[th] January 2024
Biocon's Q3 FY 2024 Results Conference Call
At 9:00 AM IST on 9[th] February 2024
The management team of Biocon Limited (BSE code: 532523, NSE Id: BIOCON) will organize a conference call for Analysts and Investors on Friday, 9[th] February 2024 at 9:00 am IST following the announcement of financial results for the quarter ended December 31[st] , 2023. The call will be conducted over Zoom.
| Conference Call Details | Conference Call Details |
|---|---|
| Date | Friday, 9thFebruary, 2024 |
| Time | 9:00 hrs - 10:30 hrs, IST |
| Registration Link | Click here |
| Recording | Will be made available within 24 hrs from the end of the call on the Company website (Biocon > Investors > Financial Information > Earnings Call Recordings) |
| Conference Call Transcript | Will be made available within 5 working days from the call date on the Company website (Biocon > Investors > Financial Information > Earnings Call Transcripts) |
Note: Participants are requested to join 10 minutes in advance of the call start time.
For further information please contact:
Saurabh Paliwal
Investor Relations – Biocon Limited P: +91 80 2808 2040/ +91 95383 80801 E: [email protected]
Safe Harbor: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current assumptions and expectations concerning future developments and their potential effects upon Biocon and its subsidiaries/associates. There can be no assurance that future developments affecting Biocon and its subsidiaries/associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties that may cause actual results to differ, possibly materially, from those contemplated by such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our Company, our directors, nor any of our subsidiaries/ associates assume any obligation to update or otherwise revise any statements reflecting circumstances arising after the conference call's conclusion to reflect the occurrence of underlying events, even if the underlying assumptions and expectations do not come to fruition.